NCT00604890已完成1 期
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
BPGbio11 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 186
- 试验地点
- 11
- 主要终点
- Number of Participants With Complete Response
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adults ≥ 18 years of age
- •Primary, histologically confirmed sBCC with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target sBCC lesion suitable for excision
- •Histological diagnosis made no more than 4 weeks prior to the screening visit
- •Histological biopsy removed 25% or less of the target lesion
- •No other dermatological disease in the sBCC target site or surrounding area
- •Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
- •Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
- •Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
- •Ability to follow study instructions and likely to complete all study requirements
- •Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist
- •Written consent to allow photographs of the target sBCC lesion to be used as part of the study data
- •For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)
排除标准
- •Pregnant or lactating
- •Presence of known or suspected systemic cancer
- •Histological evidence of nBCC, SCC, or any other tumor in the biopsy specimen
- •Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen
- •History of recurrence of the target sBCC lesion
- •Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
- •Concurrent disease or treatment that suppresses the immune system
- •Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
- •Known sensitivity to any of the ingredients in the study medication
- •Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
- •Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
- •Use of systemic retinoids within the 6 months prior to the screening period
- •Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
- •Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period
- •Treatment with the following topical agents within the 4 weeks prior to the screening visit: levulanic acid, 5-fluorouracil, coricosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
- •Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target sBCC lesion is on the face
- •Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target sBCC lesion during the 4 weeks prior to the screening visit
- •Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
- •Evidence of current chronic alcohol or drug abuse
- •Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit
- •In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study
研究组 & 干预措施
2
Placebo Comparator
Placebo cream AM ; 3% active cream PM
干预措施: Placebo (Other)
1
Experimental
Active cream, 3% AM & PM
干预措施: API 31510 3% Topical Cream (Drug)
2
Placebo Comparator
Placebo cream AM ; 3% active cream PM
干预措施: API 31510 3% Topical Cream (Drug)
3
Placebo Comparator
Placebo cream AM; 1.5% active cream PM
干预措施: API 31510 1.5% Topical Cream (Drug)
3
Placebo Comparator
Placebo cream AM; 1.5% active cream PM
干预措施: Placebo (Other)
4
Placebo Comparator
Placebo AM and PM
干预措施: Placebo (Other)
结局指标
主要结局
Number of Participants With Complete Response
时间窗: 10 weeks
To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).
次要结局
- Number of Participants With Partial Response(10 weeks)
研究者
研究点 (11)
Loading locations...
相似试验
撤回
2 期
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell CarcinomaSquamous Cell CarcinomaNCT00605709BPGbio
已完成
3 期
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big ToenailOnychomycosisNCT00443820Novartis Pharmaceuticals526
已完成
3 期
Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big ToenailOnychomycosisNCT00443898Novartis Pharmaceuticals518
撤回
2 期
A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye DiseaseDry Eye DiseaseNCT01478555Sun Pharmaceutical Industries Limited
已完成
3 期
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)Cutaneous LeishmaniasisNCT00606580U.S. Army Medical Research and Development Command375